Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 studyLihua E. Budde, Nancy L. Bartlett, Matthew Ku et al.|The Lancet Oncology|2022Cited by 429
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL studyFranck Morschhauser, Loretta J. Nastoupil, Saurabh Dahiya et al.|Nature Medicine|2024Cited by 127
Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphomaChristopher Rushton, Ryan D. Morin, Sarah E. Arthur et al.|Blood Advances|2020Cited by 120
Relapse Timing Is Associated With Distinct Evolutionary Dynamics in Diffuse Large B-Cell LymphomaLaura K. Hilton, David W. Scott, Henry S. Ngu et al.|Journal of Clinical Oncology|2023Cited by 50
Preliminary Evidence Of Anti Tumor Activity Of Selinexor (KPT-330) In a Phase I Trial Ofa First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Relapsed / Refractory Non Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)John Kuruvilla, Mansoor Raza Mirza, Martin Gutierrez et al.|Blood|2013Cited by 30